Clinical Research Directory
Browse clinical research sites, groups, and studies.
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
Sponsor: Sanofi
Summary
Primary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric oxide \[FeNO\]), and concomitant treatments for asthma. Secondary Objectives: The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT for asthma (eg, most commonly used regimens, reason for initiation of new asthma treatments, concomitant therapies, treatment durations, and reasons for discontinuation and/or switching) * To assess the effectiveness of DUPIXENT in asthma patients in a real world setting (lung function improvement, exacerbation rate, asthma control) * To assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects of treatment in comorbid conditions in asthma patients treated with Dupixent * To collect data on HealthCare Resource Utilization (HCRU) * To collect safety data on study participants in the real-world setting.
Official title: PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting
Key Details
Gender
All
Age Range
12 Years - Any
Study Type
OBSERVATIONAL
Enrollment
376
Start Date
2020-11-02
Completion Date
2026-07-01
Last Updated
2026-02-12
Healthy Volunteers
No
Conditions
Interventions
Dupilumab SAR231893
Pharmaceutical form:solution Route of administration: subcutaneous Dose regimen:
Locations (41)
Investigational Site Number : 0320005
La Plata, Buenos Aires, Argentina
Investigational Site Number : 0320006
Villa Rosa, Buenos Aires, Argentina
Investigational Site Number : 0320001
Ciudad Autonoma Bs As, Argentina
Investigational Site Number : 0320008
Ciudad Autonoma Buenos Aires, Argentina
Investigational Site Number : 0320009
San Miguel de Tucumán, Argentina
Investigational Site Number : 0320004
Santa Fe, Argentina
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Quillota, Región de Valparaíso, Chile
Investigational Site Number : 1700009
Barranquilla, Colombia
Investigational Site Number : 1700004
Bogotá, Colombia
Investigational Site Number : 1700003
Bucaramanga, Colombia
Investigational Site Number : 3760008
Ashdod, Israel
Investigational Site Number : 3760004
Ashkelon, Israel
Investigational Site Number : 3760005
Jerusalem, Israel
Investigational Site Number : 3760003
Jerusalem, Israel
Investigational Site Number : 3760001
Kfar Saba, Israel
Investigational Site Number : 3760006
Rehovot, Israel
Investigational Site Number : 3760007
Tel Aviv, Israel
Investigational Site Number : 4140001
Kuwait City, Kuwait
Investigational Site Number : 4220002
Beirut, Lebanon
Investigational Site Number : 4220001
Beirut, Lebanon
Investigational Site Number : 4220003
El Achrafiyé, Lebanon
Investigational Site Number : 4840003
Durango, Mexico
Investigational Site Number : 6340001
Doha, Qatar
Investigational Site Number : 6430005
Chelyabinsk, Russia
Investigational Site Number : 6430007
Moscow, Russia
Investigational Site Number : 6430004
Moscow, Russia
Investigational Site Number : 6430006
Rostov-on-Don, Russia
Investigational Site Number : 6430008
Saratov, Russia
Investigational Site Number : 6430002
Stavropol, Russia
Investigational Site Number : 6820005
Jeddah, Saudi Arabia
Investigational Site Number : 6820004
Mecca, Saudi Arabia
Investigational Site Number : 6820002
Riyadh, Saudi Arabia
Investigational Site Number : 6820001
Riyadh, Saudi Arabia
Investigational Site Number : 7020002
Singapore, Singapore
Investigational Site Number : 7020001
Singapore, Singapore
Investigational Site Number : 7840006
Abu Dhabi, United Arab Emirates
Investigational Site Number : 7840007
Dubai, United Arab Emirates
Investigational Site Number : 7840001
Dubai, United Arab Emirates
Investigational Site Number : 7840004
Sharjah city, United Arab Emirates
Investigational Site Number : 7840002
Sharjah city, United Arab Emirates